Name: Crispr-Cas-Based Genome Editing for Treating Human Diseases-Part a (Volume 208) (Progress in Molecular Biology and Translational Science, Volume 208) (en Inglés)
Price: 441669.00 COP
Availability: InStock
Author: Singh Vijay
ISBN: 9780443315886

portada Crispr-Cas-Based Genome Editing for Treating Human Diseases-Part a (Volume 208) (Progress in Molecular Biology and Translational Science, Volume 208) (en Inglés)

Crispr-Cas-Based Genome Editing for Treating Human Diseases-Part a (Volume 208) (Progress in Molecular Biology and Translational Science, Volume 208) (en Inglés)

Formato

Libro Físico

Editorial

Academic Press

Autor

Singh Vijay

Idioma

Inglés

N° páginas

308

Encuadernación

Tapa Dura

ISBN13

9780443315886

N° edición

Crispr-Cas-Based Genome Editing for Treating Human Diseases-Part a (Volume 208) (Progress in Molecular Biology and Translational Science, Volume 208) (en Inglés)

Singh Vijay (Autor) · Academic Press · Tapa Dura

Libro Nuevo Importado

Envío: 17 a 21 días háb.

$ 883.339$ 441.669

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 441.669

¡Envío Gratis! Llega entre el 28 Ago y el 04 Sep a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Crispr-Cas-Based Genome Editing for Treating Human Diseases-Part a (Volume 208) (Progress in Molecular Biology and Translational Science, Volume 208) (en Inglés)"

CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and more. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source. This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.